Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Simply meeting 5% growth estimates with no change in Pfizer's dirt-cheap valuation would produce over 12% annually -- boom, ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...